Cytokine and Cytokine Receptor Single-Nucleotide Polymorphisms Predict Risk for Non–Small Cell Lung Cancer among Women

Dyke, Alison L. Van; Coté, Michele L.; Wenzlaff, Angie S.; Chen, Wei; Abrams, Judith; Land, Susan; Giroux, Craig N.; Schwartz, Ann G.

doi:10.1158/1055-9965.epi-08-0962

Cited by 42 publications

(37 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taken together, the previous (Colakogullari et al 2008; Gu et al 2008; Seow et al 2006; Van Dyke et al 2009) and present studies suggested that none of the three functional IL-6 promoter polymorphisms (-174G>C, -572C>G and -6331T>C) are associated with risk of lung cancer in the Chinese population. However, when performing haplotype-based analyses, we found that the CC (-6331C and -572C) IL-6 promoter haplotype was significantly associated with increased lung cancer risk.…”

Section: Discussionsupporting

confidence: 80%

“…Several investigations have shown that the -174G>C polymorphism contributes to the pathogenesis of colorectal cancer (Landi et al 2003; Slattery et al 2009) and Kaposi sarcoma (Foster et al 2000; Gazouli et al 2004). However, molecular epidemiologic studies have not shown an association between this functional polymorphism and lung cancer susceptibility in the European population (Campa et al 2004, 2005; Colakogullari et al 2008; Engels et al 2007; Seifart et al 2005; Van Dyke et al 2009). Our metaanalysis of 83 studies involving 44,735 cases and 60,747 controls did not show a significant association between the -174G>C polymorphism and cancer risk, including lung cancer (Liu et al 2012).…”

Section: Discussionmentioning

confidence: 99%

“…Three functional polymorphisms, including -6331T>C, -572C>G (somewhere also named -634 C>G) and -174G>C, associated with IL-6 transcription activity have been found in the IL-6 promoter region (Fishman et al 1998; Nakajima et al 1999; Smith et al 2008). The -572C>G and -174G>C IL-6 promoter variants were reported not to be associated with lung cancer risk (Campa et al 2005; Engels et al 2007; Seow et al 2006; Van Dyke et al 2009). Besides, the present study has shown no association between -6331T>C or -572C>G and lung cancer risk, respectively.…”

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk

Chen

Liu

Yang

et al. 2012

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background Aberrant expression of interleukin-6 (IL-6) may play an important role in lung carcinogenesis. Whether IL-6 promoter haplotypes are associated with lung cancer risk and their functions have not yet been studied. We tested the hypothesis that single-nucleotide polymorphism (SNP) and/or haplotypes of IL-6 promoter are associated with risk of lung cancer. Methods Two functional IL-6 promoter SNPs (-6331T>C and -572C>G) were genotyped in the discovery group including 622 patients and 614 controls, and the results were replicated in an independent validation group including 615 patients and 638 controls. Luciferase reporter gene assays were conducted to examine the function of IL-6 promoter haplotypes. Results None of the functional IL-6 promoter SNPs were associated with lung cancer risk in either study. However, a two-SNP CC (-6331C and -572C) IL-6 promoter haplotype was significantly more common among cases than among controls in both groups (P = 0.031 and P = 0.035, respectively), indicating that this haplotype is associated with increased lung cancer risk {adjusted odds ratio [OR], 1.56 [95 % confidence interval (95 % CI), 1.04–2.34] and 1.51 [95 % CI, 1.03–2.22], respectively}. Combined analysis of both studies showed a strong association of this two-SNP haplotype with increased lung cancer risk (adjusted OR, 1.53; 95 % CI, 1.16–2.03; P = 0.003). Comparably, luciferase reporter assays of A549 lung cancer cell lines transfected with the CC haplotype revealed that the two-SNP haplotype had significantly higher IL-6 transcriptional activity compared with cells transfected with the common haplotype. Conclusions This is the first evidence of identifying an IL-6 promoter haplotype (CC) associated with increased risk of lung cancer.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk

Chen

Liu

Yang

et al. 2012

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Data collected on a number of risk factors for NSCLC have been published previously. 21–24 NSCLC diagnoses dates, histology, and treatment data were collected through the Metropolitan Detroit Cancer Surveillance System.…”

Section: Methodsmentioning

confidence: 99%

Survival in Women with NSCLC: The Role of Reproductive History and Hormone Use

Katcoff

Wenzlaff

Schwartz

2014

Journal of Thoracic Oncology

Self Cite

View full text Add to dashboard Cite

Introduction Although lung cancer is the leading cause of cancer death in women, few studies have investigated the hormonal influence on survival after a lung cancer diagnosis and results have been inconsistent. We evaluated the role of reproductive and hormonal factors in predicting overall survival in women with non–small-cell lung cancer (NSCLC). Methods Population-based lung cancer cases diagnosed between November 1, 2001 and October 31, 2005 were identified through the Metropolitan Detroit Surveillance, Epidemiology, and End Results Registry. Interview and follow-up data were collected for 485 women. Cox proportional hazard regression models were used to determine hazard ratios (HRs) for death after an NSCLC diagnosis associated with reproductive and hormonal variables. Results Use of hormone therapy (HT) was associated with improved survival (HR, 0.69; 95% confidence interval, 0.54–0.89), adjusting for stage, surgery, radiation, education level, pack-years of smoking, age at diagnosis, race, and a multiplicative interaction between stage and radiation. No other reproductive or hormonal factor was associated with survival after an NSCLC diagnosis. Increased duration of HT use before the lung cancer diagnosis (132 months or longer) was associated with improved survival (HR, 0.54; 95% confidence interval, 0.37–0.78), and this finding remained significant in women taking either estrogen alone or progesterone plus estrogen, never smokers, and smokers. Conclusion These findings suggest that HT use, in particular use of estrogen plus progesterone, and long-term HT use are associated with improved survival of NSCLC.

show abstract

“…IL1, IL1B, IL1RN, TNFA, IL8, COX2, and IL10 SNPs have been associated with risk of lung cancer (43,(46)(47)(48)(49)(50)(51)(52)(53). In the Detroit lung cancer case-control study, associations between lung cancer risk and SNPs varied by race and by history of COPD (54). SNPs in IL7R, IL15, TNF, TNFRSF10A, IL1RN, and IL1A were associated with lung cancer risk in women with self-reported COPD but not among women without COPD.…”

Section: Candidate Gene Studiesmentioning

confidence: 97%

Genetic Epidemiology of Cigarette Smoke–Induced Lung Disease

Schwartz

2012

Proc Am Thorac Soc

Self Cite

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) and lung cancer represent two diseases that share a strong risk factor in smoking, and COPD increases risk of lung cancer even after adjusting for the effects of smoking. These diseases not only occur jointly within an individual but also there is evidence of shared occurrence within families. Understanding the genetic contributions to these diseases, both individually and jointly, is needed to identify the highest risk group for screening and targeted prevention, as well as aiding in the development of targeted treatments. The chromosomal regions that have been identified as being associated either jointly or independently with lung cancer, COPD, nicotine addiction, and lung function are presented. Studies jointly measuring genetic variation in lung cancer and COPD have been limited by the lack of detailed COPD diagnosis and severity data in lung cancer populations, the lack of lung cancer-specific phenotypes (histology and tumor markers) in COPD populations, and the lack of inclusion of minorities. African Americans, who smoke fewer cigarettes per day and have different linkage disequilibrium and disease patterns than whites, and Asians, also with different patterns of exposure to lung carcinogens and linkage patterns, will provide invaluable information to better understand shared and independent genetic contributions to lung cancer and COPD to more fully define the highest risk group of individuals who will most benefit from screening and to develop molecular signatures to aid in targeted treatment and prevention efforts.

show abstract

Cytokine and Cytokine Receptor Single-Nucleotide Polymorphisms Predict Risk for Non–Small Cell Lung Cancer among Women

Cited by 42 publications

References 58 publications

A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk

A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk

Survival in Women with NSCLC: The Role of Reproductive History and Hormone Use

Genetic Epidemiology of Cigarette Smoke–Induced Lung Disease

Contact Info

Product

Resources

About